Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
出版年份 2023 全文链接
标题
Management of patients with HER2-positive metastatic breast cancer after trastuzumab deruxtecan failure
作者
关键词
-
出版物
ESMO Open
Volume 8, Issue 4, Pages 101608
出版商
Elsevier BV
发表日期
2023-07-18
DOI
10.1016/j.esmoop.2023.101608
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- LBA1 Unraveling the mechanism of action and resistance to trastuzumab deruxtecan (T-DXd): Biomarker analyses from patients from DAISY trial
- (2022) M.F. Mosele et al. ANNALS OF ONCOLOGY
- Trastuzumab Deruxtecan in Patients with Central Nervous System Involvement from HER2-Positive Breast Cancer: The DEBBRAH Trial
- (2022) José Manuel Pérez-García et al. NEURO-ONCOLOGY
- Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
- (2022) Javier Cortés et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Deruxtecan Improves Progression-Free Survival and Intracranial Response in Patients with HER2-Positive Metastatic Breast Cancer and Brain Metastases
- (2022) Anne Jacobson ONCOLOGIST
- Bystander effect of antibody–drug conjugates: fact or fiction?
- (2022) Federica Giugliano et al. Current Oncology Reports
- T-DM1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: a meta-analysis
- (2022) Claudia Omarini et al. BMC CANCER
- Histology-agnostic approvals for antibody–drug conjugates in solid tumours: is the time ripe?
- (2022) Chiara Corti et al. EUROPEAN JOURNAL OF CANCER
- Trastuzumab deruxtecan in HER2-positive breast cancer with brain metastases: a single-arm, phase 2 trial
- (2022) Rupert Bartsch et al. NATURE MEDICINE
- Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies
- (2022) C.A. Powell et al. ESMO Open
- LBA55 Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial
- (2022) K. Goto et al. ANNALS OF ONCOLOGY
- Trastuzumab-based regimens beyond progression: A crucial treatment option for HER2+ advanced/metastatic breast cancer
- (2022) Thibaut Sanglier et al. BREAST
- Breast Cancer Statistics, 2022
- (2022) Angela N. Giaquinto et al. CA-A CANCER JOURNAL FOR CLINICIANS
- The therapeutic window of antibody drug conjugates: A dogma in need of revision
- (2022) Raffaele Colombo et al. CANCER CELL
- Beyond HER2: Targeting the ErbB receptor family in breast cancer
- (2022) Joshua Z. Drago et al. CANCER TREATMENT REVIEWS
- Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
- (2022) Sheheryar Kabraji et al. CLINICAL CANCER RESEARCH
- Trastuzumab Deruxtecan in HER2-Positive Metastatic Breast Cancer Patients with Brain Metastases: A DESTINY-Breast01 Subgroup Analysis
- (2022) Guy Jerusalem et al. Cancer Discovery
- Preclinical Characterization and Phase I Study of an Anti–HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies
- (2022) Filip Janku et al. Cancer Immunology Research
- Margetuximab Versus Trastuzumab in Patients With Previously Treated HER2-Positive Advanced Breast Cancer (SOPHIA): Final Overall Survival Results From a Randomized Phase 3 Trial
- (2022) Hope S. Rugo et al. JOURNAL OF CLINICAL ONCOLOGY
- HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1
- (2022) Fara Brasó-Maristany et al. JNCI-Journal of the National Cancer Institute
- Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial
- (2022) Sara A Hurvitz et al. LANCET
- Targeting HER2-positive breast cancer: advances and future directions
- (2022) Sandra M. Swain et al. NATURE REVIEWS DRUG DISCOVERY
- Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer
- (2021) Hope S. Rugo et al. JAMA Oncology
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer in the APHINITY Trial: 6 Years' Follow-Up
- (2021) Martine Piccart et al. JOURNAL OF CLINICAL ONCOLOGY
- Unlocking the potential of antibody–drug conjugates for cancer therapy
- (2021) Joshua Z. Drago et al. Nature Reviews Clinical Oncology
- Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial
- (2021) José Manuel Pérez-García et al. LANCET ONCOLOGY
- Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer: phase II neoadjuvant clinical trial of T-DM1 combined with pertuzumab
- (2021) Otto Metzger Filho et al. Cancer Discovery
- LBA15 Primary outcome of the phase III SYD985.002/TULIP trial comparing [vic-]trastuzumab duocarmazine to physician’s choice treatment in patients with pre-treated HER2-positive locally advanced or metastatic breast cancer
- (2021) C. Saura Manich et al. ANNALS OF ONCOLOGY
- Antibody–Drug Conjugates for the Treatment of Breast Cancer
- (2021) Chiara Corti et al. Cancers
- Current and Future Management of HER2-Positive Metastatic Breast Cancer
- (2021) Olga Martínez-Sáez et al. JCO Oncology Practice
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
- (2021) A. Gennari et al. ANNALS OF ONCOLOGY
- Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
- (2021) Paolo Tarantino et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Key metrics to expanding the pipeline of successful antibody–drug conjugates
- (2021) Ian Nessler et al. TRENDS IN PHARMACOLOGICAL SCIENCES
- Heterogeneous HER2 Amplification—a New Clinical Category of HER2-Positive Breast Cancer?
- (2021) Alicia F.C. Okines et al. Cancer Discovery
- Interstitial Lung Disease Induced by Anti-ERBB2 Antibody-Drug Conjugates
- (2021) Paolo Tarantino et al. JAMA Oncology
- Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysis
- (2021) G. Curigliano et al. ANNALS OF ONCOLOGY
- The 2019 WHO classification of tumours of the breast
- (2020) Puay Hoon Tan et al. HISTOPATHOLOGY
- Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
- (2020) Kimberly H. Allison et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial☆
- (2020) F. Montemurro et al. ANNALS OF ONCOLOGY
- Antibody–drug conjugates in breast cancer: the chemotherapy of the future?
- (2020) Eleonora Nicolò et al. CURRENT OPINION IN ONCOLOGY
- Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
- (2020) Cristina Saura et al. JOURNAL OF CLINICAL ONCOLOGY
- Final efficacy results of neratinib in HER2-positive hormone receptor-positive early-stage breast cancer from the phase III ExteNET trial
- (2020) Arlene Chan et al. Clinical Breast Cancer
- Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Updated Results of ALTERNATIVE
- (2020) Stephen R. D. Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study
- (2019) Kenji Tamura et al. LANCET ONCOLOGY
- Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study
- (2019) Udai Banerji et al. LANCET ONCOLOGY
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
- (2018) Antonio C. Wolff et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- HER2 amplification in tumors activates PI3K/Akt signaling independent of HER3
- (2018) Ana Ruiz-Saenz et al. CANCER RESEARCH
- Global surveillance of trends in cancer survival 2000–14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries
- (2018) Claudia Allemani et al. LANCET
- Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4–1 and NRDP1, in primary breast cancer
- (2018) Satu Luhtala et al. BMC CANCER
- Trastuzumab Emtansine With or Without Pertuzumab Versus Trastuzumab Plus Taxane for Human Epidermal Growth Factor Receptor 2–Positive, Advanced Breast Cancer: Primary Results From the Phase III MARIANNE Study
- (2017) Edith A. Perez et al. JOURNAL OF CLINICAL ONCOLOGY
- 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial
- (2017) David Cameron et al. LANCET
- Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
- (2017) Véronique Diéras et al. LANCET ONCOLOGY
- Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
- (2017) Ian E Krop et al. LANCET ONCOLOGY
- Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab
- (2016) Sherene Loi et al. JAMA Oncology
- Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial
- (2015) G. Gebhart et al. ANNALS OF ONCOLOGY
- Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index
- (2015) Robert P Lyon et al. NATURE BIOTECHNOLOGY
- Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
- (2015) Sandra M. Swain et al. NEW ENGLAND JOURNAL OF MEDICINE
- Using the Lessons Learned From the Clinic to Improve the Preclinical Development of Antibody Drug Conjugates
- (2014) Dowdy Jackson et al. PHARMACEUTICAL RESEARCH
- A Pooled Analysis of 2618 Patients Treated With Trastuzumab Beyond Progression for Advanced Breast Cancer
- (2012) Fausto Petrelli et al. Clinical Breast Cancer
- Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
- (2012) Anas Younes et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
- (2012) Sunil Verma et al. NEW ENGLAND JOURNAL OF MEDICINE
- Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer
- (2010) Kimberly L. Blackwell et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study
- (2009) Gunter von Minckwitz et al. JOURNAL OF CLINICAL ONCOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now